As previously disclosed, an exclusive distributor agreement has been signed with the company Mediq Sverige AB regarding marketing and sales of Calmark's Neo products in Sweden. A marketing and launch plan has been drawn up and Mediq has now placed a first clinical order.

"I am glad that our Neo products will also start to be used in Sweden," says Magdalena Tharaldsen, Director International Business Development at Calmark. "I look forward to soon receiving feedback from the Swedish healthcare system on how Neo-Bilirubin contributes to more effective diagnostics for neonatal jaundice."

This information is information that Calmark Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 3 May 2023, 10:25 CEST.

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.

‍